Current guidelines recommend extending the use of dual antiplatelet therapy (DAPT) beyond 1 year in patients with an acute coronary syndrome (ACS) and a high risk of ischaemia and low risk of bleeding. No data exist about the implementation of this strategy in older adults from routine clinical practice. The aim of this cohort study is to assess the proportion of potential candidates ≥ 65 years who received extended DAPT (i.e., for more than 1 year) and identify the variables associated with extended treatment.
Featured article: Extended use of dual antiplatelet therapy among older adults with acute coronary syndromes and associated variables
Articles
-
-
Anlotinib dramatically improved pulmonary hypertension and hypoxia caused by Pulmonary Tumor Thrombotic Microangiopathy (PTTM) associated with gastric carcinoma: a case report
-
Extended use of dual antiplatelet therapy among older adults with acute coronary syndromes and associated variables: a cohort study
-
Platelet indices and blood pressure: a multivariable mendelian randomization study
-
Low awareness of venous thromboembolism among neurosurgical hospitalized patients: a cross-sectional study
-
Heparin-induced thrombocytopenia: an update
-
Laboratory assessment of rivaroxaban: a review
-
Practical management of patients on apixaban: a consensus guide
-
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
-
Hereditary thrombophilia
Recommended reading
Incidence of thromboembolism in patients with COVID-19: a systematic review and meta-analysis
Kochawan Boonyawat, Pichika Chantrathammachart, Pawin Numthavaj, Nithita Nanthatanti, Sithakom Phusanti, Angsana Phuphuakrat, Pimjai Niparuck & Pantep Angchaisuksiri
Risk factors of thrombosis in Chinese subjects with acute promyelocytic leukemia
Xueya Zhang & Xizhe Guo
Thrombosis and bleeding outcomes in the treatment of cerebral venous thrombosis in cancer
Nadia I Abelhad, Wei Qiao, Naveen Garg &
Cristhiam M. Rojas-Hernandez
Serial markers of coagulation and inflammation and the occurrence of clinical pulmonary thromboembolism in mechanically ventilated patients with SARS-CoV-2 infection; the prospective Maastricht intensive care COVID cohort
Mark M. G. Mulder, LIoyd Brandts, Renée A. G. Brüggemann, Marcel Koelmann, Alexander S. Streng, Renske H. Olie, Hester A. Gietema, Henri M. H. Spronk, Iwan C. C. van der Horst, Jan-Willem E. M. Sels, Joachim E. Wildberger, Sander M. J. van Kuijk, Ronny M. Schnabel, Hugo ten Cate, Yvonne M. C. Henskens & Bas C. T. van Bussel
Trending articles
Click here to view the most shared articles in the last month!
Aims and scope
Thrombosis Journal is an open-access journal that publishes original articles on aspects of clinical and basic research, new methodology, case reports and reviews in the areas of thrombosis.
Topics of particular interest include the diagnosis of arterial and venous thrombosis, new antithrombotic treatments, new developments in the understanding, diagnosis and treatments of atherosclerotic vessel disease, relations between haemostasis and vascular disease, hypertension, diabetes, immunology and obesity.
Latest Tweets
View Twitter timeline
Your browser needs to have JavaScript enabled to view this timeline
Asian-Pacific Society on Thrombosis and Hemostasis
The Asian-Pacific Society of Thrombosis and Hemostasis (APSTH) is a non-profit organization that welcomes any medical or scientific professionals with an interest in the field of thrombosis and hemostasis, particularly those professionals from the Asia Pacific Region.
The main objectives of APSTH are to foster and advance clinical and scientific knowledge in the field of thrombosis, hemostasis and vascular biology through promotion of scientific exchange via meetings, publications, and promotion of international cooperation in clinical studies, and standardization of nomenclature and practices in the Asia-Pacific region.
Editors' quotes
“It is with great pleasure that I join the Editorial team of Thrombosis Journal and to take on the role as co-Editor-in-Chief (EiC). This is indeed a great honor for me. For your information, I am a biochemist and have been active in the field of Thrombosis and Haemostasis with a particular interest in fibrinolysis for over 38 years. I am looking forward to making a positive contribution to Thrombosis Journal. I would very much like to thank and acknowledge the many years at the helm by my predecessor Prof Hugo Ten Cate. I will do my best to fill Hugo’s shoes. I would also like to acknowledge the long-lasting role of Yukio Ozaki as co-EiC who will be continuing in this role. I am looking forward to working with Prof Ozaki and the dedicated Associate Editors to develop and implement new ideas and approaches to improve the standing of the Journal.”
Robert Medcalf, Editor-in-Chief, Thrombosis Journal
"Treatment and prophylaxis of thrombotic and bleeding disorders is of great importance to the worldwide population, and there is a great need to facilitate the research activities related to this field. The aim of Thrombosis Journal is to provide a platform on which these important studies are visible to all members of the scientific community and public."
Yukio Ozaki, Editor-in-Chief, Thrombosis Journal
Official journal of
-
Thrombosis Journal is the official journal of the Asian-Pacific Society on Thrombosis and Hemostasis.
Members of APSTH are entitled to a 15% discount on the article processing charge.
Follow
Annual Journal Metrics
-
Citation Impact
5.509 2-Year-Impact-Factor (2021)
4.466 5-Year-Impact-Factor - Impact Factor (2021)
1.126 - Source Normalized Impact per Paper (SNIP)
1.004 - SCImago Journal Rank (SJR)Speed
48 days to first decision for all manuscripts (Median)
49 days to first decision for reviewed manuscripts only (Median)Usage
540,660 Downloads (2021)
549 Altmetric mentions (2021)